According to GlobalData’s medical device pipeline database, 22 Ultrasound Contrast Agents (Microbubbles) devices are in various stages of development globally. GlobalData’s report provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, nine are in active development, while the remaining 13 are in an inactive stage of development. There are five products in the early stages of development, and the remaining four are in the late stages of development.
Microbubbles act as acoustic backscatters’; in that they enhance image quality through the utilization of different operation modes. This imaging mode exploits the ability of microbubbles to expand, contract and resonate when an ultrasound wave is initiated. Microbubbles are principally used in the enhancement of blood, thus allowing clinicians to track its flow through tissues and organs of interest. This allows for the analysis of blood volume, tissue perfusion and organ edge delineation; whilst allowing for an assessment of tumor and lesion vascularization. Within this market, ultrasound contrast is only tracked for use in echocardiography. Brands include Definity (Luminity outside of the US) and SonoVue.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
See Also:
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Ultrasound Contrast Agents (Microbubbles) pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Ultrasound Contrast Agents (Microbubbles) devices. Overall, most of these Ultrasound Contrast Agents (Microbubbles) pipeline devices are being developed by private entities.
Key players involved in the active development of Ultrasound Contrast Agents (Microbubbles) include Microvascular Therapeutics, NuvOx Pharma, Praxis Pharmaceutical SAU, Solstice Pharmaceuticals, Sonnest, Stanford University, Stanford University, Thomas Jefferson University, University of Pittsburgh and University of Texas Southwestern Medical Center.
For a complete picture of the developmental pipeline for Ultrasound Contrast Agents (Microbubbles) devices, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
